FindTrial
Sign In

Norepinephrine for the management of hypotension in premature and full-term neonates

Norepinephrine for the management of hypotension in premature and full-term neonates - Norepinephrine for hypotension in neonates

Status
Unknown
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON42050
Enrollment
28
Registered
2015-05-28
Start date
Unknown
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hypotension low blood pressure

Interventions

Hypotension
Neonates
Norepinephrine

Sponsors

Universitair Medisch Centrum Sint Radboud
Lead Sponsor

Eligibility

Age
2 Years to 11 Years

Inclusion criteria

Inclusion criteria: 1) A gestational age between 24+0 and 42+0 weeks 2)

Exclusion criteria

Exclusion criteria: 1) Chromosomal defects 2) Major congenital malformations that increase the risk of death or adverse neurodevelopmental outcome 3) Infants with hypotension during treatment with extracorporeal membrane oxygenation

Design outcomes

Primary

MeasureTime frame
Primary outcome measure is change in blood pressure and systemic blood flow.—

Secondary

MeasureTime frame
Secondary outcomes are effects on the cardiac function, effects on the pulmonary condition, effects on tissue perfusion and adverse effects during hospitalization.—

Countries

The Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)